Psilocybin therapy is a supervised treatment approach that combines psilocybin, the psychoactive compound found in certain mushrooms, with structured psychological support before, during, and after the experience. Unlike traditional psychiatric medications taken daily, psilocybin therapy typically involves just one or two dosing sessions, each embedded in a broader course of psychotherapy. It is currently being studied in over 130 clinical trials for conditions including depression, anxiety, and existential distress, though it has not yet received FDA approval.
How a Psilocybin Therapy Session Works
Psilocybin therapy follows a three-phase structure: preparation, the dosing session itself, and integration afterward. Each phase is considered essential to the treatment, not just the drug experience in isolation.
During preparation, you meet with a therapist (sometimes two) over one or more sessions to build trust, discuss your intentions, and learn what to expect. This is partly practical and partly psychological. You’ll talk about your mental health history, what you hope to gain, and how to navigate difficult emotions if they arise during the experience.
The dosing session takes place in a comfortable, controlled setting, often a room designed to feel more like a living room than a clinic. You lie down, wear an eye mask, and listen to music while the psilocybin takes effect. The experience typically lasts four to six hours, with one or two trained facilitators present the entire time. Their role is not to direct the experience but to provide a calm, supportive presence. Clinical trials have used doses in the range of 20 to 30 milligrams, adjusted for body weight, which is enough to produce a full psychedelic experience including altered perception, intense emotions, and sometimes vivid imagery or a sense of deep personal insight.
Integration is what happens afterward, usually across multiple therapy sessions in the days and weeks following. This is where you work with a therapist to process what came up during the experience, identify meaningful themes, and translate any insights into lasting changes. Integration draws from a range of therapeutic approaches including acceptance and commitment therapy, psychodynamic therapy, mindfulness practices, and somatic techniques. Some programs also use group therapy or journaling. The goal is to help the psychological shifts from the session take root in everyday life rather than fading over time.
What Psilocybin Does in the Brain
Psilocybin works primarily by activating serotonin receptors, which triggers a cascade of changes in how different brain regions communicate with each other. The most consistent finding across brain imaging studies is that psilocybin disrupts a brain network called the default mode network. This network is active when you’re reflecting on yourself, ruminating, or mentally time-traveling to the past or future. In people with depression, the default mode network tends to be overactive, locked into rigid, repetitive patterns of self-focused thought.
Psilocybin decreases connectivity within this network while simultaneously increasing communication between brain regions that don’t normally talk to each other. The brain shifts from a modular, compartmentalized state to a more globally interconnected one. Researchers believe this is what underlies the subjective experience of dissolving mental boundaries, seeing problems from new perspectives, and feeling a sense of connection to something larger than yourself. Importantly, these connectivity changes aren’t just a temporary blip. Brain imaging in depressed patients has shown reduced default mode network rigidity lasting up to three weeks after a single dose, suggesting the brain doesn’t simply snap back to its old patterns once the drug wears off.
Conditions Being Treated
Depression is the most studied application. The FDA granted breakthrough therapy designation for psilocybin in 2018 for treatment-resistant depression and again in 2019 for major depressive disorder. Breakthrough designation doesn’t mean the drug is approved. It means the FDA considers the early evidence promising enough to fast-track the review process. Several Phase 2 and Phase 3 trials are underway, and the earliest possible approvals are still estimated to be a few years out, assuming positive results.
Psilocybin therapy is also being actively studied for anxiety and existential distress in people with advanced cancer. Facing a terminal diagnosis often brings intense fear of death, loss of meaning, and a kind of psychological suffering that conventional treatments struggle to reach. The National Cancer Institute is currently running a Phase 2b trial examining psilocybin-assisted psychotherapy for patients with stage 3 or 4 cancer, looking at whether it reduces clinically significant anxiety and depression. Earlier pilot studies in this population suggested meaningful benefits, which motivated the larger trial.
Beyond depression and end-of-life distress, researchers are exploring psilocybin therapy for alcohol use disorder, tobacco addiction, obsessive-compulsive disorder, anorexia, and post-traumatic stress. A 2024 review cataloged 134 clinical trials spanning more than 54 potential indications. Most of these are still in early stages, but the breadth of research reflects how wide the potential applications may be.
What Makes It Different From Antidepressants
Traditional antidepressants like SSRIs work by keeping serotonin available in the brain on an ongoing basis. You take them daily, they build up over weeks, and if you stop, the effects wear off. Psilocybin therapy works on a fundamentally different model. One or two sessions, combined with therapy, aim to produce lasting changes by disrupting entrenched neural patterns and opening a window of psychological flexibility. The drug isn’t doing the ongoing work. It’s creating conditions under which therapy and personal insight can reach deeper.
This distinction matters for people with treatment-resistant depression, meaning those who haven’t improved after trying multiple conventional medications. For this group, the prospect of a single-dose intervention that works through a different mechanism is particularly compelling, which is why the FDA flagged it as a breakthrough therapy.
Where It’s Legally Available
Psilocybin remains a Schedule 1 controlled substance under federal law in the United States, classified alongside heroin as having no accepted medical use and high abuse potential. That classification hasn’t changed despite the breakthrough therapy designations, which apply only to the drug development pathway, not to legal access.
Oregon became the first state to create a regulated framework for psilocybin services. Under Oregon law, licensed service centers can offer supervised psilocybin sessions to adults. You can only purchase, possess, and consume psilocybin products at a licensed service center and only under the direct supervision of a trained facilitator. These centers cannot be located in areas zoned exclusively for residential use. This is not a prescription model. No diagnosis is required, but the experience must happen on-site with professional oversight.
Colorado has passed similar legislation and is in the process of building out its regulatory framework. A handful of cities across the country have also deprioritized enforcement of psilocybin possession laws, though deprioritization is not the same as legalization or regulated therapeutic access.
Risks and Limitations
Psilocybin therapy is not risk-free. The experience itself can be psychologically intense and sometimes distressing. Clinical research participants have reported episodes of fear, confusion, and paranoia during sessions, though these are generally manageable with trained support and often resolve within the session itself. Survey data from both clinical and non-clinical settings suggest that even highly challenging experiences can be associated with increased well-being afterward, but that doesn’t mean the difficulty is trivial in the moment.
People with a personal or family history of psychotic disorders are typically excluded from clinical trials because psilocybin could potentially trigger or worsen psychotic symptoms. It also interacts with certain psychiatric medications, particularly SSRIs, which can blunt psilocybin’s effects or create unpredictable interactions. Anyone considering psilocybin therapy while on existing medications needs to understand these interactions beforehand.
The biggest limitation right now is access. With zero FDA-approved psilocybin products on the market and only two states offering regulated services, most people cannot legally receive this treatment in a clinical setting. The underground market exists but lacks the preparation, professional support, and integration that clinical research consistently identifies as essential to safe, effective outcomes.